Date: 2016-03-16
Type of information: R&D agreement
Compound: CAR-T cell-based oncology therapies
Company: GSK (UK) Miltenyi Biotec (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration R&D
Action mechanism: cell therapy/gene therapy/CAR-T cell therapy.
Disease:
Details: * On March 16, 2016, GSK and Miltenyi Biotec announced a strategic collaboration that will bring together GSK’s expertise in developing cell and gene therapy based treatments with Miltenyi Biotec’s global leadership in cell processing and related technologies in cell therapy. The collaboration seeks to optimise the manufacture and delivery of these personalised therapies using increased automation and leading edge processing technology. Through the collaboration, Miltenyi Biotec will engage with GSK to integrate greater automation and high-tech processing technology into GSK’s current cell and gene therapy R&D manufacturing capabilities. The goal is to use this increased automation to further industrialise cell and gene therapy, overcoming the manufacturing and scale-up constraints associated with current, more manual cell and gene therapy processes. This could reduce the costs and geographical barriers associated with this treatment approach, speed development of therapies and support their potential beyond rare diseases and limited populations. The collaboration will also bring together the technology and expertise of both companies to advance the discovery of new CAR (chimeric antigen-receptor) T-cell based therapeutics. GSK and Miltenyi Biotec will collaborate on defined CAR-T oncology targets and on the development of advancements in technologies in this space that may be further applied by both companies. This collaboration supplements GSK’s existing CAR-T preclinical portfolio.
Financial terms:
Latest news:
